New data Presented at ERS 2017 on flutiform® k-haler®(fluticasone propionate and formoterol), Mundipharma's Novel Breath-triggered Aerosol Inhaler
Cambridge, England (ots/PRNewswire) - - flutiform k-haler achieved high levels of lung deposition of over 44% of delivered dose - Plume force of flutiform k-haler was compared with fluticasone propionate/salmeterol xinafoate delivered via the Seretide® Evohaler® pMDI and Sirdupla® pMDI devices - Pharmacokinetic ...